The latest Investing Matters Podcast with Jean Roche, Co-Manager of Schroder UK Mid Cap Investment Trust has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPureTech Share News (PRTC)

Share Price Information for PureTech (PRTC)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 227.50
Bid: 226.50
Ask: 228.00
Change: 0.00 (0.00%)
Spread: 1.50 (0.662%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 227.50
PRTC Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Puretech Health proposes $100m capital return

Tue, 19th Mar 2024 09:46

(Sharecast News) - Biotherapeutics company PureTech Health has proposed a capital return of $100.0m to its shareholders by way of a tender offer.

PureTech said on Tuesday that the proposed capital return represented approximately 14% of its market capitalisation based on Monday's closing price and noted that it follows a previous announcement that it will receive approximately $293.0m in gross proceeds from its remaining stake in Karuna.

The AIM-listed group said the offer will be launched after the publication of its full-year results in April, subject to market conditions, and will require shareholder approval.

PureTech added that if the full $100.0m was not returned, then it intends to return any remainder following the completion of the offer, by way of a special dividend.

Chief executive Daphne Zohar said: "PureTech's mission is to generate value both for patients and shareholders, and Bristol Myers Squibb's acquisition of our Founded Entity Karuna Therapeutics for $14.0bn is a testament to our execution on both fronts. We directed $18.5m to the founding and development of Karuna, and not only have we created a potential breakthrough treatment that may change the lives of millions of people living with schizophrenia, but we have also been able to generate $1.1bn in cash for PureTech, with potentially more to come. These resources enabled us to create an exciting crop of new medicines that position us to repeat and scale this type of outcome - and we have done so without diluting our shareholders in over six years.

"We are delighted to be able to purchase shares of PureTech at this valuation and to concurrently provide some liquidity to our shareholders and additional capital returns beyond the recently completed $50.0m share buyback. Following this proposed tender offer, we are confident that our strong balance sheet will continue to support the development of our existing pipeline - as well as the next wave of innovative medicines. Looking forward, the board will continue to assess ongoing opportunities to improve shareholder returns."

As of 1055 GMT, PureTech shares were up 8.58% at 221.50p.

Reporting by Iain Gilbert at Sharecast.com

More News
9 Apr 2020 12:54

PureTech Health Swings To Annual Profit On Exceptional Gains

PureTech Health Swings To Annual Profit On Exceptional Gains

Read more
9 Apr 2020 09:09

Puretech Health revenues slide, losses widen

(Sharecast News) - Clinical-stage biotherapeutics company Puretech Health posted weaker full-year revenues and a widened operating loss on Thursday and also noted it was yet to see any impact to ongoing work as a result of the Covid-19 outbreak.

Read more
2 Apr 2020 16:09

UK Earnings, Trading Statements Calendar - Next 7 Days

UK Earnings, Trading Statements Calendar - Next 7 Days

Read more
3 Mar 2020 16:07

PureTech Health Doses First Patient In Phase 1 LYT-100 Study

PureTech Health Doses First Patient In Phase 1 LYT-100 Study

Read more
3 Mar 2020 08:04

PureTech begins next study of lymphoedema drug candidate

(Sharecast News) - Clinical-stage biotherapeutics company PureTech Health announced on Tuesday that the first participant has been dosed in a clinical study of 'LYT-100', its wholly-owned product candidate for the potential treatment of lymphoedema and other fibrotic conditions.

Read more
25 Feb 2020 14:10

PureTech Health Affiliate Akili Posts Encouraging ADHD Study Results

PureTech Health Affiliate Akili Posts Encouraging ADHD Study Results

Read more
24 Jan 2020 12:45

Friday broker round-up

(Sharecast News) - TT Electronics: Jefferies downgrades to hold with a target price of 265p.

Read more
23 Jan 2020 07:44

PureTech sells shares in Karuna affiliate for $200m

(Sharecast News) - Clinical stage biotech company PureTech Health said it had sold 2.1m shares of its affiliate Karuna Therapeutics for $200m.

Read more
15 Jan 2020 13:26

PureTech Health Unit Akili's AKL-T01 Study Achieves Primary Endpoint

PureTech Health Unit Akili's AKL-T01 Study Achieves Primary Endpoint

Read more
19 Dec 2019 17:33

PureTech Health Affiliate Reports Positive Results In Alopecia Study

PureTech Health Affiliate Reports Positive Results In Alopecia Study

Read more
19 Dec 2019 08:25

PureTech affiliate Follica reports 44% improvement in hair-loss study

(Sharecast News) - PureTech Health on Thursday said results from a study into a hair loss treatment developed by its affiliate Follica demonstrated a statistically significant 44% improvement in hair count.

Read more
17 Dec 2019 16:13

PureTech's Gelesis Partners With Telehealth Firm Ro For Plenity In US

PureTech's Gelesis Partners With Telehealth Firm Ro For Plenity In US

Read more
12 Dec 2019 15:52

PureTech Health Investee Akili Delivers Positive AKL-T03 Trial Results

PureTech Health Investee Akili Delivers Positive AKL-T03 Trial Results

Read more
10 Dec 2019 14:47

PureTech Health's Vedanta Launches First-In-Patient Study Of VE800

PureTech Health's Vedanta Launches First-In-Patient Study Of VE800

Read more
9 Dec 2019 12:32

PureTech Health Investee Gelesis Gets USD85 Million For Plenity Launch

PureTech Health Investee Gelesis Gets USD85 Million For Plenity Launch

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.